DC
BBIO icon

Diametric Capital’s BridgeBio Pharma BBIO Stock Holding History

Diametric Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$692K Buy
+9,295
New +$651K 0.07% 283
2024
Q3 		– Sell
-12,076
Closed -$306K – 380
2024
Q2 		$306K Buy
+12,076
New +$330K 0.17% 176

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Diametric Capital's BBIO Position: Q2 2026 in Review

Diametric Capital opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 9,295 shares worth $692K. The stake represents 0.07% of the portfolio and ranks #283 among its holdings. This is a return to the name: Diametric Capital previously reported a position in BBIO as recently as Q2 2024.

Diametric Capital first reported a position in BBIO in Q2 2024 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Diametric Capital held 9,295 shares of BridgeBio Pharma worth $692K as of Q2 2026.
  • BridgeBio Pharma was a new Diametric Capital position in Q2 2026.
  • BridgeBio Pharma made up 0.07% of Diametric Capital's portfolio in Q2 2026, its #283 holding.
  • Diametric Capital first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 2 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.